Taken together, these data suggested that the induction of PDE4D expression by roflumilast synergized with IFN-α activity to reduce the intracellular cAMP level and potentiates the antiproliferative effect of IFN-α on bladder cancer cells. Here, IFNA1 is linked to urinary bladder cancer.